Omeros (OMER) to Release Quarterly Earnings on Monday

Omeros (NASDAQ:OMER - Get Free Report) will be issuing its quarterly earnings data after the market closes on Monday, April 1st. Individual that wish to listen to the company's earnings conference call can do so using this link.

Omeros Stock Up 0.9 %

Shares of OMER stock traded up $0.03 during trading hours on Thursday, reaching $3.45. 331,192 shares of the company's stock were exchanged, compared to its average volume of 593,240. The stock's fifty day moving average price is $3.90 and its two-hundred day moving average price is $2.97. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 10.80. Omeros has a 1 year low of $0.92 and a 1 year high of $7.80. The stock has a market cap of $216.90 million, a PE ratio of 10.78 and a beta of 1.38.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Omeros from a "hold" rating to a "sell" rating in a report on Tuesday.

Institutional Investors Weigh In On Omeros

Institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. acquired a new stake in Omeros during the 2nd quarter worth approximately $27,000. Gilbert & Cook Inc. acquired a new position in Omeros in the fourth quarter valued at about $45,000. Walleye Trading LLC bought a new position in Omeros in the third quarter valued at about $50,000. O Shaughnessy Asset Management LLC bought a new stake in shares of Omeros during the third quarter worth $50,000. Finally, ExodusPoint Capital Management LP acquired a new position in Omeros in the 1st quarter valued at approximately $54,000. Institutional investors own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.